Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease - PubMed (original) (raw)
Comparative Study
. 2010 Nov;133(11):3336-48.
doi: 10.1093/brain/awq277. Epub 2010 Oct 8.
Heather J Wiste, Prashanthi Vemuri, Stephen D Weigand, Matthew L Senjem, Guang Zeng, Matt A Bernstein, Jeffrey L Gunter, Vernon S Pankratz, Paul S Aisen, Michael W Weiner, Ronald C Petersen, Leslie M Shaw, John Q Trojanowski, David S Knopman; Alzheimer's Disease Neuroimaging Initiative
Affiliations
- PMID: 20935035
- PMCID: PMC2965425
- DOI: 10.1093/brain/awq277
Comparative Study
Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease
Clifford R Jack Jr et al. Brain. 2010 Nov.
Abstract
Biomarkers of brain Aβ amyloid deposition can be measured either by cerebrospinal fluid Aβ42 or Pittsburgh compound B positron emission tomography imaging. Our objective was to evaluate the ability of Aβ load and neurodegenerative atrophy on magnetic resonance imaging to predict shorter time-to-progression from mild cognitive impairment to Alzheimer's dementia and to characterize the effect of these biomarkers on the risk of progression as they become increasingly abnormal. A total of 218 subjects with mild cognitive impairment were identified from the Alzheimer's Disease Neuroimaging Initiative. The primary outcome was time-to-progression to Alzheimer's dementia. Hippocampal volumes were measured and adjusted for intracranial volume. We used a new method of pooling cerebrospinal fluid Aβ42 and Pittsburgh compound B positron emission tomography measures to produce equivalent measures of brain Aβ load from either source and analysed the results using multiple imputation methods. We performed our analyses in two phases. First, we grouped our subjects into those who were 'amyloid positive' (n = 165, with the assumption that Alzheimer's pathology is dominant in this group) and those who were 'amyloid negative' (n = 53). In the second phase, we included all 218 subjects with mild cognitive impairment to evaluate the biomarkers in a sample that we assumed to contain a full spectrum of expected pathologies. In a Kaplan-Meier analysis, amyloid positive subjects with mild cognitive impairment were much more likely to progress to dementia within 2 years than amyloid negative subjects with mild cognitive impairment (50 versus 19%). Among amyloid positive subjects with mild cognitive impairment only, hippocampal atrophy predicted shorter time-to-progression (P < 0.001) while Aβ load did not (P = 0.44). In contrast, when all 218 subjects with mild cognitive impairment were combined (amyloid positive and negative), hippocampal atrophy and Aβ load predicted shorter time-to-progression with comparable power (hazard ratio for an inter-quartile difference of 2.6 for both); however, the risk profile was linear throughout the range of hippocampal atrophy values but reached a ceiling at higher values of brain Aβ load. Our results are consistent with a model of Alzheimer's disease in which Aβ deposition initiates the pathological cascade but is not the direct cause of cognitive impairment as evidenced by the fact that Aβ load severity is decoupled from risk of progression at high levels. In contrast, hippocampal atrophy indicates how far along the neurodegenerative path one is, and hence how close to progressing to dementia. Possible explanations for our finding that many subjects with mild cognitive impairment have intermediate levels of Aβ load include: (i) individual subjects may reach an Aβ load plateau at varying absolute levels; (ii) some subjects may be more biologically susceptible to Aβ than others; and (iii) subjects with mild cognitive impairment with intermediate levels of Aβ may represent individuals with Alzheimer's disease co-existent with other pathologies.
Figures
Figure 1
Illustrative images. Left: Mild cognitive impairment progressor, Top: positive PIB PET. Bottom: MRI illustrating atrophic hippocampi and ventricular enlargement. Right: Mild cognitive impairment non-progressor. Top: negative PIB PET with non-specific white matter retention but no cortical retention. Bottom: MRI illustrating normal hippocampi and no ventricular enlargement.
Figure 2
Risk profile as a function of increasing biomarker severity among all 218 subjects with mild cognitive impairment. Log hazard of progressing to dementia as a function of (A) increasing hippocampal volume (adjusting for total intercranial volumes) and (B) increasing brain Aβ amyloid load within all 218 subjects with mild cognitive impairment. Hash marks at the bottom of the plot indicate the hippocampal volume and Aβ load measures of individual subjects with mild cognitive impairment, with APOE genotype (ε4 carrier gold, non-carrier blue) and progressor versus non-progressor status indicated.
Figure 3
Hypothetical effects of pure Alzheimer’s pathology versus mixed pathology on time-to-progression from mild cognitive impairment to dementia. Clinical disease stage is indicated on the horizontal axis with vertical lines indicating the time at which diagnoses of mild cognitive impairment and dementia are reached. The severity of Aβ load (red curve) and brain atrophy (blue curve) on the vertical axis range from normal to maximally abnormal. (A) [modified from Jack et al. (2010)], illustrates the hypothetical biomarker curves of Subject A, who progresses from normal to mild cognitive impairment to dementia and who has pure Alzheimer’s pathology. Over the time a subject traverses the horizontal ‘clinical distance’ from time-of diagnosis of mild cognitive impairment to time-of diagnosis of dementia (indicated by the horizontal red and blue arrows), the vertical ‘distance travelled’ along the Aβ load biomarkers curve is small as indicated by the red vertical arrow in (A). In contrast, over this same ‘clinical distance travelled’ on the horizontal axis, the vertical distance travelled along the MRI biomarker is substantial as indicated by the blue vertical arrow in (A). (B) illustrates the hypothetical curve of Subject B, who has mixed pathology. The effect of the coexistent second pathology is to shift the blue atrophy curve, time-of diagnosis of mild cognitive impairment, and time-of diagnosis of dementia closer to the Aβ curve. Consequently Subject B reaches a diagnosis of dementia with a lower level of Aβ in situ than Subject A. AD = Alzheimer’s disease; MCI = mild cognitive impairment.
Comment in
- Multiple imputation models should incorporate the outcome in the model of interest.
Bartlett JW, Frost C, Carpenter JR. Bartlett JW, et al. Brain. 2011 Nov;134(Pt 11):e189; author reply e190. doi: 10.1093/brain/awr061. Epub 2011 Jun 6. Brain. 2011. PMID: 21646332 Free PMC article. No abstract available.
Similar articles
- Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease.
Jack CR Jr, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS, Shiung MM, Gunter JL, Boeve BF, Kemp BJ, Weiner M, Petersen RC; Alzheimer's Disease Neuroimaging Initiative. Jack CR Jr, et al. Brain. 2009 May;132(Pt 5):1355-65. doi: 10.1093/brain/awp062. Epub 2009 Mar 31. Brain. 2009. PMID: 19339253 Free PMC article. - Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study.
Villain N, Chételat G, Grassiot B, Bourgeat P, Jones G, Ellis KA, Ames D, Martins RN, Eustache F, Salvado O, Masters CL, Rowe CC, Villemagne VL; AIBL Research Group. Villain N, et al. Brain. 2012 Jul;135(Pt 7):2126-39. doi: 10.1093/brain/aws125. Epub 2012 May 23. Brain. 2012. PMID: 22628162 - Basal forebrain atrophy correlates with amyloid β burden in Alzheimer's disease.
Kerbler GM, Fripp J, Rowe CC, Villemagne VL, Salvado O, Rose S, Coulson EJ; Alzheimer's Disease Neuroimaging Initiative. Kerbler GM, et al. Neuroimage Clin. 2014 Nov 27;7:105-13. doi: 10.1016/j.nicl.2014.11.015. eCollection 2015. Neuroimage Clin. 2014. PMID: 25610772 Free PMC article. - Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative.
Veitch DP, Weiner MW, Aisen PS, Beckett LA, Cairns NJ, Green RC, Harvey D, Jack CR Jr, Jagust W, Morris JC, Petersen RC, Saykin AJ, Shaw LM, Toga AW, Trojanowski JQ; Alzheimer's Disease Neuroimaging Initiative. Veitch DP, et al. Alzheimers Dement. 2019 Jan;15(1):106-152. doi: 10.1016/j.jalz.2018.08.005. Epub 2018 Oct 13. Alzheimers Dement. 2019. PMID: 30321505 Review. - Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials.
Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC, Harvey D, Jack CR Jr, Jagust W, Morris JC, Petersen RC, Saykin AJ, Shaw LM, Toga AW, Trojanowski JQ; Alzheimer's Disease Neuroimaging Initiative. Weiner MW, et al. Alzheimers Dement. 2017 Apr;13(4):e1-e85. doi: 10.1016/j.jalz.2016.11.007. Epub 2017 Mar 22. Alzheimers Dement. 2017. PMID: 28342697 Free PMC article. Review.
Cited by
- Characterizing the clinical heterogeneity of early symptomatic Alzheimer's disease: a data-driven machine learning approach.
Wang X, Ye T, Jiang D, Zhou W, Zhang J; Alzheimer’s Disease Neuroimaging Initiative. Wang X, et al. Front Aging Neurosci. 2024 Aug 12;16:1410544. doi: 10.3389/fnagi.2024.1410544. eCollection 2024. Front Aging Neurosci. 2024. PMID: 39193492 Free PMC article. - The impacts of sex and the 5xFAD model of Alzheimer's disease on the sleep and spatial learning responses to feeding time.
Campbell KJ, Jiang P, Olker C, Lin X, Kim SY, Lee CJ, Song EJ, Turek FW, Vitaterna MH. Campbell KJ, et al. Front Neurol. 2024 Jul 31;15:1430989. doi: 10.3389/fneur.2024.1430989. eCollection 2024. Front Neurol. 2024. PMID: 39144714 Free PMC article. - Prevalence and clinicopathological features of primary age-related tauopathy (PART): A large forensic autopsy study.
Yoshida K, Hata Y, Ichimata S, Tanaka R, Nishida N. Yoshida K, et al. Alzheimers Dement. 2024 Aug;20(8):5411-5420. doi: 10.1002/alz.14037. Epub 2024 Jun 28. Alzheimers Dement. 2024. PMID: 38938196 Free PMC article. - Double-Edged Sword: A Positive Brain Scan Result Heightens Confidence in an Alzheimer's Diagnosis But Also Leads to Higher Stigma Among Older Adults in a Vignette-Based Experiment.
Stites SD, Lee BN, Largent EA, Harkins K, Sankar P, Krieger A, Brown RT. Stites SD, et al. J Gerontol B Psychol Sci Soc Sci. 2024 Aug 1;79(8):gbae109. doi: 10.1093/geronb/gbae109. J Gerontol B Psychol Sci Soc Sci. 2024. PMID: 38869988
References
- American Psychiatric Association. Diagnostic and statistical manual of mental disorders, DSM-IV. Washington DC: American Psychiatric Association; 1994.
- Apostolova LG, Dutton RA, Dinov ID, Hayashi KM, Toga AW, Cummings JL, et al. Conversion of mild cognitive impairment to Alzheimer disease predicted by hippocampal atrophy maps. Arch Neurol. 2006;63:693–9. - PubMed
- Bennett DA, Schneider JA, Bienias JL, Evans DA, Wilson RS. Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions. Neurology. 2005a;64:834–41. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- P50 AG16574/AG/NIA NIH HHS/United States
- R01 AG11378/AG/NIA NIH HHS/United States
- AG024904/AG/NIA NIH HHS/United States
- R01 AG011378/AG/NIA NIH HHS/United States
- C06 RR018898/RR/NCRR NIH HHS/United States
- U01 AG06786/AG/NIA NIH HHS/United States
- R01 AG011378-19/AG/NIA NIH HHS/United States
- U19 AG010483/AG/NIA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical